米国市場銘柄情報

SYK ストライカー

銘柄追加

335.610
-1.540-0.46%

終値 04/26 16:00 ET

1,276.89億時価総額40.68直近PER

ストライカーに関するコメント

ログインコメントを投稿

Moomoo AI

02/09 18:58

The recent insider sale of Stryker shares at the current price is viewed negatively. However, high insider ownership is seen positively, suggesting management's consideration for shareholders. Yet, the absence of insider buying over the past year is worrisome.

Don't Ignore The Insider Selling In Stryker

Moomoo AI

02/02 19:31

The EPS decline doesn't align with share price changes, indicating other factors. Management might be prioritizing revenue growth over EPS. The company's recent performance improvement suggests potential business momentum.

Despite the Downward Trend in Earnings at Stryker (NYSE:SYK) the Stock Climbs 9.4%, Bringing Five-year Gains to 97%

コラムStryker Shares Surge 6.3% as 2024 Outlook, Q4 Results Beat Estimates

$ストライカー(SYK.US)$ shares advanced 6.6% after the company gave a better-than-expected outlook for 2024 and delivered an earnings beat, prompting analysts to upgrade the stock.
The company sees 2024 adjusted earnings to reach $11.70 to $12 a share, according to its press release. That's higher than the $11.54 estimate of analysts polled by Capital IQ, according to MT Newswires.
"Based on our momentum for 2023, strong proce...

Editor's Picks: Community Q4 earnings insights & highlights

Moomoo AI

2023/12/31 20:39

Investors feel Stryker's high P/E ratio is justified due to its favorable earnings outlook. Their optimism on consistent earnings growth maintains the elevated ratio as expectations for a drop in earnings are low. A significant change in conditions could alter this supportive investor sentiment.

Investors Still Waiting For A Pull Back In Stryker Corporation (NYSE:SYK)

Analysts Notebook

2023/12/27 18:18

コラムBiotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$S&P 500 Index(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

Moomoo AI

2023/12/25 03:28

Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.

Baird Names Top Medtech Picks for 2024; Bullish on Alcon, Axonics

Moomoo AI

2023/12/20 21:21

Stryker has proven its ability to reinvest capital at good rates of return, and with consistency in returns, it can potentially yield favorable share price returns. Despite some risks, this stock is worth further exploration.

Slowing Rates Of Return At Stryker (NYSE:SYK) Leave Little Room For Excitement

Moomoo AI

2023/12/09 22:30

Insiders at Stryker have been selling shares without making any purchases in the past year, a potential red flag despite the company's profitability and growth. The absence of insider purchases raises caution, even though significant insider ownership generally aligns with shareholder interest.

Stryker Insiders Sell US$153m Of Stock, Possibly Signalling Caution

Moomoo AI

2023/10/22 00:25

BofA Securities backs these picks for their great quality, consistent execution, and profitability, leading to quick compounded earnings, despite GLP-1 drugs sector uncertainties. Novo Nordisk's SELECT trial financial figures will be a key aspect in November.

Boston Sci, Stryker, Dexcom, Shockwave Are BoA's Top Medtech Picks

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気